Aventis Pharmaceuticals Inc.

Santhera Pharmaceuticals (schweiz) Ag

Via Pharmaceuticals, Inc.

Cesare Mondadori

Janice M Hitchcock

Stephen M Sorensen

Ulrich Abel

Stefano Biondi

Holger Deppe

Fernando Camacho

George A Keesler

Inge Ott

Zhengbin Yao

Christian Rummey

Miroslav Terinek

Marco Henneböhle

Holger Herzner

Hervé Siendt

Philipp Weyermann

Mustapha Abarghaz

Barbara Hoffmann-Enger

Jérôme Duranton

Emmanuelle Limanton

Patrick Wagner

Michael Soeberdt

Sonja Nordhoff

Günther Metz

The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin-4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amytrophic lateral sclerosis (ALS), anxiety and depression.

Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists

The invention relates to compounds having PDE2 inhibitory activities, as well as therapeutic methods by administering said compounds, in particular for treating various diseases of the central or peripheral nervous system. It further deals with pharmaceutical compositions comprising said compounds and methods for preparing said compounds.

Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof

A method of providing symptomatic relief from sleep induced insomnia in a patient comprising administering an effective amount of R-(+)-&#x3b1;-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

Use of R (+)-&#x3b1;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia

A method of treating a patient for a Sleep Disorder comprising administering an effective amount of R-(&plus;)-&agr;-(2,3-Dimethoxyphenyl)-1-&lsqb;2-(4-fluorophenyl)ethyl&rsqb;-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.

Use of R(&plus;) -&agr;-(2,3-Dimethoxyphenyl)-1-&lsqb;2-(4-fluorophenyl)ethyl&rsqb;-4-piper idinemethanol for the treatment of sleep disorders

The present invention is directed to methods to identify test compounds that alter circadian rhythms of mammals, and more specifically, directed to methods for determining the ability of a test compound to alter hCKI &dgr; and &egr; phosphorylation of a human Period protein. The present invention is also directed to a method for determing the ability of a test compound to selectively alter phosphorylation, interaction with, or alternatively degradation, of one or more human Period proteins relative to its ability to alter phosphorylation, interaction with, or alternatively degradation, of a different human Period protein.

Screening methods for altering circadian rhythms and for human casein kinase I &dgr; and/or &egr; phosphorylation of human clock proteins, period 1, -2 and -3

The present invention is directed to the use of (&plus;)-&agr;-(2,3-dimethoxyphenyl)-1-&lsqb;2-(4-fluorophenyl)ethyl&rsqb;-4-piperidinemethanol in treating Depressive Disorders and Bipolar Disorders.

Use of (&plus;)-&agr;-(2,3-dimethoxyphenyl)-1-&lsqb;2-(4-fluorophenyl) ethyl&rsqb;-4-piperidinemethanol in treating depressive disorders and bipolar disorders

Use of R- &plus;)-&agr;-(2,3-dimethoxyphenyl-1-&lsqb;2-(4-fluorophenyl) ethyl&rsqb;-4-piperidinemethanol for the treatment of sleep disorders

Growing community of inventors

Reinach, Switzerland

Cesare Mondadori